Health Canada clears Appili Therapeutics for new phase 3 trial to assess Avigan to prevent Covid-19

This article was originally published here

Health Canada has provided a ‘No Objection Letter (NOL)’ for Appili’s proposed study; the U.S. FDA accepted a submission of a protocol amendment to conduct the trial in

The post Health Canada clears Appili Therapeutics for new phase 3 trial to assess Avigan to prevent Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply